Supplier
Accredo Health Group INC
Accredo Health Group INC was paid $165.63M by Medicaid between Jan 2018 and Dec 2024, across 28 billing codes. Its largest line is J2326, Injection, nusinersen, 0.1 mg — 49% of everything it billed.
33Billing provider infoACCREDO HEALTH GROUP INC
MEMPHIS, TN 38134
MEMPHIS, TN 38134
33aNPI1346208949assigned 05/03/2006
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$165.63M
24GClaims46,758
24DCodes billed28
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Tennessee
Rank by total paid#1 of 296
Median peer was paid$15K
This provider vs. median10,732×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PERINI, VIC controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,755 | $16.13M | |
| 2019 | 3,646 | $24.17M | |
| 2020 | 9,000 | $35.96M | |
| 2021 | 12,716 | $35.39M | |
| 2022 | 9,988 | $31.12M | |
| 2023 | 5,820 | $15.32M | |
| 2024incomplete | 3,833 | $7.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2326 | Injection, nusinersen, 0.1 mg | 49% | 953 | 640 | $80.91M |
| J2357 | Injection, omalizumab, 5 mg | 12% | 8,421 | 6,608 | $20.68M |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | 9.1% | 9,507 | 8,601 | $15.04M |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | 7.2% | 7,721 | 6,946 | $12.00M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 4.9% | 7,839 | 7,549 | $8.14M |
| J3285 | Injection, treprostinil, 1 mg | 2.4% | 594 | 429 | $3.92M |
| J0517 | Injection, benralizumab, 1 mg | 2.2% | 954 | 872 | $3.70M |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | 2.2% | 1,000 | 907 | $3.68M |
| 90378 | 1.9% | 1,519 | 1,015 | $3.21M | |
| J0584 | Injection, burosumab-twza 1 mg | 1.9% | 183 | 120 | $3.15M |
| J7686 | Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg | 1.7% | 1,589 | 884 | $2.82M |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | 1.6% | 1,312 | 999 | $2.62M |
16 more codes
| J2182 | Injection, mepolizumab, 1 mg | 1.1% | 708 | $1.89M |
| J3490 | Unclassified drugs | <1% | 125 | $904K |
| J2323 | Injection, natalizumab, 1 mg | <1% | 107 | $831K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 981 | $723K |
| J3241 | Injection, teprotumumab-trbw, 10 mg | <1% | 14 | $595K |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | <1% | 259 | $277K |
| J0897 | Injection, denosumab, 1 mg | <1% | 144 | $163K |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 156 | $107K |
| Q0513 | Pharmacy dispensing fee for inhalation drug(s); per 30 days | <1% | 816 | $103K |
| S9347 | Home infusion therapy, uninterrupted, long-term, controlled rate intravenous or subcutaneous infusion therapy (e.g., epoprostenol); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 240 | $60K |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | <1% | 487 | $42K |
| J7325 | Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | <1% | 101 | $32K |
| J1325 | Injection, epoprostenol, 0.5 mg | <1% | 14 | $23K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | <1% | 540 | $2K |
| S5001 | Prescription drug, brand name | <1% | 19 | $870.17 |
| S9999 | Sales tax | 0% | 455 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPERINI, VIC (ASSISTANT SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Accredo Health Group INC | Warrendale, PA | $130.92M |
| Accredo Health Group INC | Irving, TX | $27.68M |
| Accredo Health Group INC | Corona, CA | $20.28M |
| Accredo Health Group INC | Tempe, AZ | $9.15M |
| Accredo Health Group INC | Lenexa, KS | $945K |
| Accredo Health Group INC | Marlborough, MA | $480K |
| Accredo Health Group INC | Las Vegas, NV | $480K |
| Accredo Health Group INC | New Orleans, LA | $266K |
| Accredo Health Group INC | Hoover, AL | $247K |
| Accredo Health Group INC | Greensboro, NC | $243K |
| Accredo Health Group INC | Oklahoma City, OK | $174K |
| Accredo Health Group INC | Novi, MI | $33K |
| Accredo Health Group INC | Pine Brook, NJ | $17K |
| Accredo Health Group INC | Englewood, CO | $6K |
| Accredo Health Group INC | Elmhurst, IL | $3K |
| Accredo Health Group INC | Norcross, GA | $481.79 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.